XTX Topco Ltd Acquires Shares of 17,306 AxoGen, Inc. (NASDAQ:AXGN)

XTX Topco Ltd bought a new position in AxoGen, Inc. (NASDAQ:AXGN) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 17,306 shares of the medical equipment provider’s stock, valued at approximately $285,000.

Other large investors have also recently modified their holdings of the company. R Squared Ltd purchased a new stake in AxoGen in the 4th quarter worth about $30,000. US Bancorp DE purchased a new stake in shares of AxoGen in the fourth quarter worth approximately $30,000. Harvest Fund Management Co. Ltd bought a new stake in shares of AxoGen during the 4th quarter worth approximately $93,000. Fox Run Management L.L.C. purchased a new position in AxoGen during the 4th quarter valued at $169,000. Finally, Sei Investments Co. bought a new position in AxoGen in the 4th quarter valued at $188,000. Institutional investors own 80.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on AXGN. Lake Street Capital initiated coverage on shares of AxoGen in a research report on Monday, March 17th. They set a “buy” rating and a $30.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $24.00 target price on shares of AxoGen in a research report on Wednesday, March 5th. Finally, Canaccord Genuity Group increased their price target on AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, February 26th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, AxoGen currently has an average rating of “Buy” and an average price target of $22.60.

Insider Activity

In other news, Director Amy Mcbride Wendell sold 5,000 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $20.02, for a total value of $100,100.00. Following the sale, the director now owns 97,899 shares in the company, valued at $1,959,937.98. This represents a 4.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Erick Wayne Devinney sold 15,111 shares of the company’s stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $17.50, for a total transaction of $264,442.50. Following the completion of the sale, the insider now directly owns 217,762 shares in the company, valued at approximately $3,810,835. The trade was a 6.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.00% of the company’s stock.

AxoGen Trading Up 1.5 %

AxoGen stock opened at $16.40 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. The stock has a market cap of $727.24 million, a PE ratio of -51.25 and a beta of 1.00. The stock has a 50-day moving average of $17.43 and a two-hundred day moving average of $16.17. AxoGen, Inc. has a one year low of $5.55 and a one year high of $21.00.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.